Starting at a higher dose or increasing the dose too quickly can increase the risk of adverse events and side effects
These includes typical areas such as the abdomen, hips, and thighs, but also encompass less common regions like the Double Chin Area, Love Handles, Bingo wings, Flanks and waist, Bra Bulge, Underarms and armpits, and arms
Or maybe youre already on them
The next decade of obesity drug development is a tuning exercise, not a discovery exercise, and the IP positions that will matter most are the narrow molecular claims that lock in specific ratios
Back to Journals Drug Design, Development and Therapy Volume 16 Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP Authors Wang L Received 26 January 2022 Accepted for publication 18 May 2022 Published 25 May 2022 Volume 2022:16 Pages 15471559 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Prof